The attention on cases of heart inflammation that are reported in young or very young people, especially males, after the messenger RNA vaccine has been high since June when the data from the USA and Israel arrived. Over the weeks, new data has been added on a much wider audience. And also corrections such as in the case of a Canadian study, published on a pre-print platform, which contained numbers that were rectified and imposed an apology from the University of Ottawa’s Hearth Institute. Now the data are in line with other studies.
Myocarditis and pericarditis, potentially associated with the two approved messenger RNA vaccines, Pfizer-Biontech and Moderna, “are rare events, with generally mild manifestations and a favorable outcome” as the Italian Journal of Cardiology writes, which publishes a Expert Opinion of the Italian Society of Cardiology, edited by about fifteen experts, including Gianfranco Sinagra (Cardiomyopathies Diagnosis and Treatment Center, Trieste University), Giuseppe Mercuro (Medical Sciences and Public Health Department, Cagliari University), Pasquale Perrone Filardi of the Dept. Advanced Biomedical Sciences, University of Naples.
The study reports that, at present and reviewed data in hand, the estimated overall incidence is 1 case per 100 thousand individuals, or more than 10 times lower than that of myocarditis not attributable to vaccines (10 – 20 cases per 100,000). Notwithstanding the rare nature of the event, the estimated rate is higher in subjects under 30, fully immunized and male (40 per million among men and 4.2 among women). From age 30 and up, the rates drop to 2.4 and 1.0 per million in men and women, respectively.
The benefit / risk balance, according to experts, he is clearly in favor of vaccination against Covid: in unvaccinated subjects and with Sars Cov 2 myocarditis and pericarditis are in the order of 11 cases compared to 2.7 cases out of 100 thousand. In particular, it is necessary to supervise the males under the age of 30 who complete the vaccination cycle. The study proposes for the first time a precise classification of post-vaccination forms, facilitating the identification and construction of research registers and provides guidelines for mRna vaccination in specific subgroups of the population ”.